Testing a new mRNA cancer treatment for advanced solid tumors
Part of Cancer clinical trials.
This early-stage trial tests a new medicine called NCP-IL-22BP mRNA, given as an injection, to see if it is safe and well-tolerated in patients with advanced cancers that have not responded to standard treatments. The medicine is designed to boost your immune system to fight cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old
- Advanced cancer (solid tumor) that has spread or come back after at least two lines of prior treatment, with no standard options left
- Good overall health (ECOG score 0–1, meaning you can do most daily activities)
- Expected to live at least 3 months
- Normal blood counts, liver and kidney function, and heart function (ejection fraction ≥50%)
- At least 4 weeks since last chemotherapy or radiation, and 6 weeks since certain older cancer drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This trial tests a new drug, IL-22BP/LNP, for people with advanced solid tumors (like soft tissue sarcoma, head and neck cancer, melanoma) that have worsened after standard treatments. The main goals are to see if the drug is safe and tolerable, and to learn if it might help shrink or slow the cancer.
This early-stage trial tests a new drug that combines a peptide with genetic material (siRNA) designed to help your immune system fight advanced cancers that haven't responded to standard treatments. Researchers want to see if it's safe and whether it can shrink tumors.
This early-phase trial tests NB002, a new immune-targeting medicine, to find safe doses and see how well it can treat advanced or metastatic solid cancers that have not responded to standard treatments. It may help by strengthening the immune system’s ability to fight the tumor.
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
This trial tests a new mRNA-based treatment injected directly into solid tumors that haven't responded to standard therapy. The goal is to help your immune system recognize and attack cancer cells.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.